These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21996985)

  • 1. Tissue-based molecular markers for renal cell carcinoma.
    Rink M; Chun FK; Robinson B; Sun M; Karakiewicz PI; Bensalah K; Fisch M; Scherr DS; Lee RK; Margulis V; Shariat SF
    Minerva Urol Nefrol; 2011 Dec; 63(4):293-308. PubMed ID: 21996985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
    Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
    Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
    Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
    Ingels A; Hew M; Algaba F; de Boer OJ; van Moorselaar RJ; Horenblas S; Zondervan P; de la Rosette JJ; Pilar Laguna Pes M
    World J Urol; 2017 Jan; 35(1):81-87. PubMed ID: 27207480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers in renal cell carcinoma.
    McGuire BB; Fitzpatrick JM
    Curr Opin Urol; 2009 Sep; 19(5):441-6. PubMed ID: 19584732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status and future directions of molecular markers in renal cell carcinoma.
    Rini BI
    Curr Opin Urol; 2006 Sep; 16(5):332-6. PubMed ID: 16905977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
    Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y
    Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic factors in renal cell carcinoma].
    Wen JJ; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):850-3. PubMed ID: 24507112
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
    Pantuck AJ; Zeng G; Belldegrun AS; Figlin RA
    Clin Cancer Res; 2003 Oct; 9(13):4641-52. PubMed ID: 14581333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in patients with advanced renal cell carcinoma.
    Muriel López C; Esteban E; Berros JP; Pardo P; Astudillo A; Izquierdo M; Crespo G; Sanmamed M; Fonseca PJ; Martínez-Camblor P
    Clin Genitourin Cancer; 2012 Dec; 10(4):262-70. PubMed ID: 22959659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features.
    Alshenawy HA
    Pathol Oncol Res; 2015 Sep; 21(4):893-9. PubMed ID: 25712789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
    Tang PA; Vickers MM; Heng DY
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive biomarkers in renal cell carcinoma.
    Vickers MM; Heng DY
    Target Oncol; 2010 Jun; 5(2):85-94. PubMed ID: 20582732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.
    Minardi D; Lucarini G; Filosa A; Milanese G; Zizzi A; Di Primio R; Montironi R; Muzzonigro G
    Int J Immunopathol Pharmacol; 2008; 21(2):447-55. PubMed ID: 18547492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
    Nishikawa M; Miyake H; Harada K; Fujisawa M
    Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgically induced ischemia has no impact on protein expression levels of HIF-1α and related biomarkers in renal cell carcinoma.
    Mikkelsen ML; Marcussen N; Rabjerg M
    APMIS; 2021 Sep; 129(9):535-547. PubMed ID: 33948984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease.
    Campbell L; Al-Jayyoussi G; Gutteridge R; Gumbleton N; Griffiths R; Gumbleton S; Smith MW; Griffiths DF; Gumbleton M
    J Transl Med; 2013 Oct; 11():255. PubMed ID: 24119769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.